Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis

EMBO Journal

Volumn 20, Issue 15, 2001, Pages 4163-4172

  Matas, D ^a   Sigal, A ^a   Stambolsky, P ^a   Milyavsky, M ^a   Weisz, L ^a   Schwartz, D ^a   Goldfinger, N ^a   Rotter, V ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Apoptosis; c myc; Mutant p53; Transcription activity

Indexed keywords

ALPHA AMANITIN; AMINO ACID; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; MUTANT PROTEIN; MYC PROTEIN; PROTEIN P53;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TRANSACTIVATION;

ALANINE; AMANITINS; APOPTOSIS; CELL LINE; CISPLATIN; DACTINOMYCIN; DOXORUBICIN; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; HUMANS; INTERCALATING AGENTS; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MYC; RNA POLYMERASE II; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; VALINE;

EID: 0035421961     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/20.15.4163     Document Type: Article

References (90)

1. Involvement of p53 in cell differentiation and development
2. Transcription abnormalities potentiate apoptosis of normal human fibroblasts
3. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis
4. Mutant p53 gain of function: Differential effects of different p53 mutants on resistance of cultured cells to chemotherapy
5. Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability
6. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes
7. p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage
8. In vitro analysis of the dominant negative effect of p53 mutants
9. c-myc antisense oligodeoxy-nucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice
10. Animal DNA-dependent RNA polymerases. 11. Mechanism of the inhibition of RNA polymerases B by amatoxins
11. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens
12. Assays of cell viability: Discrimination of cells dying by apoptosis
13. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells
14. Studies on the inhibition by α-amanitin of single-step addition reactions and productive RNA synthesis catalysed by wheat-germ RNA polymerase II
15. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53
16. Gain of function mutations in p53
17. c-myc plays a role in cellular susceptibility to death receptor-mediated and chemotherapy-induced apoptosis in human monocytic leukemia U937 cells
18. Inhibitors of transcription such as 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole and isoquinoline sulfonamide derivatives (H-8 and H-7) promote dephosphorylation of the carboxyl-terminal domain of RNA polymerase II largest subunit
19. Regulation of p53 downstream genes
20. WAF1, a potential mediator of p53 tumor suppression
21. Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain
22. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
23. p53 and apoptosis
24. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
25. Etoposide: Four decades of development of a topoisomerase II inhibitor
26. Induction of apoptosis in HeLa cells by trans-activation-deficient p53
27. Anthracyclines in the treatment of cancer. An overview
28. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness
29. Molecular epidemiology of human cancer: Contribution of mutation spectra studies of tumor suppressor genes
30. Molecular epidemiology and carcinogenesis: Endogenous and exogenous carcinogens
31. Gain-of-function p53 mutations enhance alteration of the T-cell receptor following X-irradiation, independently of the cell cycle and cell survival
32. The dual role model for p53 in maintaining genomic integrity
33. A transactivation-deficient mouse model provides insights into trp53 regulation and function
34. Participation of p53 protein in the cellular response to DNA damage
35. Oncogenic forms of p53 inhibit p53-regulated gene expression
36. Resistance to 195mPt-radiolabeled cis-diaminedichloroplatinum (II) of SHOK cells transfected with various oncogenes
37. p53: Puzzle and paradigm
38. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function
39. Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis
40. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain
41. Activation of the insulin-like growth factor II transcription by aflatoxin B1 induced p53 mutant 249 is caused by activation of transcription complexes; implications for a gain-of-function during the formation of hepatocellular carcinoma
42. Murine hepatocyte apoptosis induced in vitro and in vivo by TNF-α requires transcriptional arrest
43. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin
44. p53, the cellular gatekeeper for growth and division
45. Mutant p53 protein expression interferes with p53-independent apoptotic pathways
46. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein
47. Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants
48. Inhibition of RNA polymerase II as a trigger for the p53 response
49. Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells
50. A mutant p53 antagonizes the deregulated c-myc-mediated enhancement of apoptosis and decrease in leukemogenicity
51. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
52. p53 status and the efficacy of cancer therapy in vivo
53. Transcriptional activation of the human epidermal growth factor receptor promotor by human p53
54. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells
55. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPb (NF-IL6) activity by p53 species
56. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide
57. Advanced mammalian gene transfer: High titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line
58. Resistance to anticancer drugs in NIH3T3 cells transfected with c-myc and/or c-H-ras genes
59. Structural and functional involvement of p53 in BER in vitro and in vivo
60. Cooperation between p53-dependent and p53-independent apoptotic pathway of myeloid cells
61. Stabilization of the MDM2 oncoprotein by mutant p53
62. p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis
63. p53, a transformation-related cellular encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells
64. Essential role for p53-mediated transcription in E1A-induced apoptosis
65. p53-dependent cell cycle control: Response to genotoxic stress
66. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
67. Identification of minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding
68. Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome
69. The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis
70. The cellular response to p53: The decision between life and death
71. Modulation of cis-platinum resistance in Friend erythroleukemia cells by c-myc
72. Dominant negative effect of a germ-line mutant p53: A step fostering tumorigenesis
73. Overlapping domains on the p53 protein regulate its transcriptional activation and repression functions
74. Genomic instability and its role in neoplasia
75. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer
76. Functional domains of wild-type and mutant p53 proteins involved in transcriptional regulation, transdominant inhibition and transformation suppression
77. Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines
78. Effects of an inducible anti-sense c-myc gene transfer in a drug-resistant human small-cell-lung-carcinoma cell line
79. waf1/cip1
80. Maintaining genetic stability through TP53 mediated checkpoint control
81. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene
82. Regulation of p53 function
83. The transcriptional elongation inhibitor 5, 6-dichloro-1-β-D-ribofuranosylbenzimidazole inhibits transcription factor IIH-associated protein kinase
84. Generation of high-titer pseudotyped retroviral vectors with very broad host range
85. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53
86. Cisplatin and DNA repair in cancer chemotherapy
87. A temperature-sensitive mutant of human p53
88. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization